Browse Studies — Arctuva

Phase 1

A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AML

The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) …

Acute Myeloid LeukemiaAcute Myeloid Leukemia RecurrentLeukemia+1 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06152809

Phase 2

A Phase II Study of Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor With Fractionated Gemtuzumab Ozogamicin (CLAG-GO) for the Treatment of Patients With Persistent, Relapsed or Refractory Acute Myeloid Leukemia

This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) a…

Acute Myeloid Leukemia, AdultAcute Myeloid Leukemia RecurrentAcute Myeloid Leukemia, Relapsed, Adult

Estimated

~$10 – $6,250

University of Maryland, BaltimoreNCT04050280

Phase 1

Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid Leukemia

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This pr…

Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT05735184